NEW YORK (GenomeWeb News) – BioTime subsidiary OncoCyte today announced that it will collaborate with the Wistar Institute on the development of a gene expression-based lung cancer test.

Under the agreement, OncoCyte scientists will use the firm's cancer diagnostic test, PanC-Dx, to analyze levels of tumor-associated proteins in blood samples from patients in an ongoing study conducted by Wistar. Scheduled to wrap up in mid-2104, two thirds of the planned total of 600 samples have already been collected in the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.